Royalty Pharma plc
RPRX
$31.28
$0.110.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.41% | 5.29% | -0.17% | -16.96% | 5.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.41% | 5.29% | -0.17% | -16.96% | 5.36% |
| Cost of Revenue | 314.39% | -182.13% | -11.94% | 391.23% | -124.77% |
| Gross Profit | -36.13% | 205.70% | 9.38% | -102.76% | 161.81% |
| SG&A Expenses | 14.20% | -0.90% | 14.85% | -32.72% | -19.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,479.41% | -144.27% | -7.51% | 213.05% | -103.89% |
| Operating Income | -41.02% | 385.38% | 8.35% | -115.40% | 360.23% |
| Income Before Tax | -53.41% | 560.53% | -44.67% | -100.84% | 217.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.41% | 560.53% | -44.67% | -100.84% | 217.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 43.50% | -425.13% | 25.33% | 105.38% | -245.02% |
| Net Income | -57.88% | 654.34% | -55.19% | -98.60% | 208.39% |
| EBIT | -41.02% | 385.38% | 8.35% | -115.40% | 360.23% |
| EBITDA | -- | -- | -- | -- | 361.29% |
| EPS Basic | -68.11% | 655.78% | -55.24% | -98.60% | 207.50% |
| Normalized Basic EPS | -52.54% | 736.64% | 220.44% | -151.85% | -46.84% |
| EPS Diluted | -68.08% | 658.56% | -55.20% | -98.61% | 175.42% |
| Normalized Diluted EPS | -36.41% | 747.40% | 225.50% | -153.05% | -60.32% |
| Average Basic Shares Outstanding | 32.09% | -0.18% | 0.14% | 0.68% | 0.83% |
| Average Diluted Shares Outstanding | -1.41% | -1.40% | -1.48% | -1.61% | 35.10% |
| Dividend Per Share | 5.00% | 5.00% | 5.00% | 5.00% | 5.26% |
| Payout Ratio | 1.49% | -0.86% | 1.34% | 74.48% | 1.98% |
